| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the * Department of Medicine and
Department of Neurology, Emory University
School of Medicine, Atlanta, Georgia.
| Correspondence to: Dr J. Lisa Tenover, Division of Geriatric Medicine, Wesley Woods Health Center, 1841 Clifton Road NE, Atlanta, GA 30329 (e-mail: jtenove{at}emory.edu). |
| Received for publication March 26, 2007; accepted for publication July 2, 2007. |
 |
Abstract |
|---|
 Top Abstract MethodsResultsDiscussionReferences |
|---|
Key words: Aging, testosterone replacement, memory, visual spatial function
Randomized controlled trials of T replacement therapy in older men have enrolled small numbers, partly because of uncertainties about T-related morbidity, including prostate health (Liverman and Blazer, 2004). Some studies have examined T replacement in men with low endogenous levels and others have studied those with normal baseline T levels, and the duration of T treatment has been limited, ranging from 1 to 12 months (Janowsky et al, 1994; Sih et al, 1997; Janowsky et al, 2000; Cherrier et al, 2001; Kenny et al, 2002). Results have varied, from showing improvement in working memory (Janowsky et al, 2000), verbal memory (Cherrier et al, 2001), and spatial cognition (Janowsky et al, 1994) to no change in performance on cognitive tests (Sih et al, 1997; Kenny et al, 2002).
We hypothesized that prolonged replacement of T for up to 3 years in
healthy older men with low serum T levels would lead to improved performance
on cognitive tests and that adding finasteride, a 5
-reductase
inhibitor, to potentially protect the prostate from any adverse effects of the
replacement T, would not affect the T-induced improvement in cognitive
performance significantly. We also hypothesized that the effect of T
treatment, compared with placebo, would be more pronounced after 3 years of
treatment compared with a shorter treatment duration.
|
Methods |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
Study Design
Participants were randomized by computer-generated assignment in permuted
blocks of 6 to 1 of 3 treatment groups: 1) T-only group, T enanthate (TE; 200
mg intramuscularly every 2 weeks; Schein Pharmaceuticals, Florham Park, NJ)
plus placebo pill orally daily; 2) T+F group, TE 200 mg intramuscularly every
2 weeks plus finasteride (5 mg/d orally; Merck & Co, Rahway, NJ); or 3)
placebo group, sesame oil injections, 1 mL intramuscularly every 2 weeks, plus
placebo pill daily. Testosterone therapy was by intramuscular injection
because this study was initiated before the availability of reliable
transdermal T. The sample size was estimated by assessing for a 1% change in
bone mineral density, the primary endpoint of the study. Results of study
treatment as regards bone, prostate, and other safety parameters have been
reported previously (Amory et al,
2004).
Participants were treated for a total of 36 months. Only the research pharmacist and safety monitoring board knew the randomization assignment. A nurse administered the injections, and 98% occurred within 2 days of the scheduled time. Compliance was 95% on the basis of monthly pill counts of daily finasteride or placebo in the enrolled subjects. The study design included the potential for dose reductions of T or placebo injection for a hematocrit of more than 52% on safety monitoring tests.
Measurements
Blood was drawn in the morning at baseline and just before the injections
every 2 week throughout the study, including after 4, 12, 24, and 36 months of
treatment. Serum was stored frozen at –70° until the end of the
study, when samples were concurrently assayed in duplicate for each
participant. Testosterone, dihydrotestosterone (DHT), bioavailable T, and
estradiol (E2) assays have been reported previously
(Amory et al, 2004).
Cognitive tests were all done at baseline, 4 months, and 36 months. Testing was performed at the end of the 2-week T injection period, just before the next injection, and thus at the nadir T level for each participant. Tests were conducted on a separate day to avoid testing after fasting. All evaluations were made by the same psychometrist throughout the entire study. The psychometrist was blinded to the participants' group membership. The following cognitive domains were evaluated: attention (sequencing of numbers with a pencil [Trails A; US Army, 1944] and forward and backward sequencing of numbers presented orally [Digit Span test; Wechsler, 1981]), executive functioning (alternation between numbers and letters with a pencil [Trails B; US Army, 1944]), visuospatial skills (judgment of the angular orientation of lines [Judgment of Line Orientation test; Benton et al, 1983]), visual memory (immediate and delayed recall of designs [Benton Visual Retention test; Benton, 1974]), and verbal memory (learning and recall of words [Selective Reminding test; Buschke, 1973]). Assessment of baseline depression and anxiety were also performed with the Beck Depression Inventory (Beck et al, 1961) and the Speilberger State-Trait Anxiety Questionnaire (Speilberger, 1983), respectively. Three alternative forms were available for assessing verbal and visual memory, and these forms were counterbalanced across study participants and time periods.
Statistical Analysis
One-way analyses of variance were performed for each neuropsychological
measure, examining potential differences among the 3 participant groups at
baseline, 4 months, and 36 months. Repeated measures analyses of variance were
also performed for participants who received all 3 assessments.
|
Results |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
|
Mean nadir serum total T, bioavailable T, and total estradiol (E2) levels in the T-only and T+F groups significantly increased throughout the treatment period (Table 1), whereas these hormone levels did not change in the placebo group. Nadir serum total T and E2 levels tended to be higher in the T+F group compared with the T-only group, but this difference did not reach statistical significance for any time point for total T and was only significant at month 36 for E2. Serum DHT levels did not change throughout the treatment period in the placebo group but increased slightly in the T-only group by month 36 and, as expected, decreased significantly in the T+F group (Table 1). The maximum decline in serum DHT was to 47% of baseline, which was reached by month 4.
For the subset of men from whom blood was sampled at multiple times throughout the 2-week T dosing period (6 men in the placebo group, 7 men in the T-only group, and 9 men in the T+F group), peak serum total T levels were at or above the normal serum T range for the 2 T treatment groups, with mean peak value for the T-only group being 35.9 ± 12.1 nmol/L and that for the T+F group being 43.5 ± 7.6 nmol/L. Average total T levels during the 2-week dosing interval were 25.8 ± 6.9 for the T-only group, 33.0 ± 6.4 for the T+F group, and 11.8 ± 2.3 nmol/L for the placebo group. Between the 2 treatment groups, peak T levels were not different (P = .13), but the average total T levels were somewhat higher in the T+F group (P = .04).
As reported previously (Amory et al, 2004), increase in serum PSA in the T-only group was small but significant (P < .001 by month 36) but did not change in the other 2 treatment groups (Table 1). Prostate volume increased significantly in all treatment groups over the 36-month period, but the increase in volume in the T+F treatment group was small and significantly less (P = .02) than the increase in prostate volume of the placebo and T-only groups, with the latter 2 groups having a similar increase in volume over the 36 months (Table 1).
Among the 6 cognitive measures administered during this study, 1 index of
attention (ie, reversing a series of digits) was statistically significantly
different (P < .05) at 36 months
(Table 2). The T-only group
correctly reversed more digits (
± SE,
8.38 ± 0.49) than the T+F group (6.64 ± 0.44) and the placebo
group (6.63 ± 0.47). One index of verbal memory also was statistically
significantly different (Table
2). The T+F group recalled more words (46.07 ± 1.72) than
the T-only group (40.25 ± 1.61) and the placebo group (38.38 ±
2.32). Otherwise, cognitive differences between the treatment and placebo
groups were not observed in any other cognitive domain and its associated
dependent variables.
|
Repeated measures analyses of variance were performed for a subset of those
patients (n = 46) who completed all 3 assessments. Group and Time for the
number of intrusions on the Selective Reminding test interacted significantly
(P < .05). The T-only and T+F groups exhibited a decline in the
number of intrusions ( ± SE for
baseline, 4 months, and 36 months, respectively): T-only: 1.94 ± 0.32,
0.94 ± 0.32, 0.75 ± 0.21 and T+F: 1.79 ± 0.57, 1.29
± 0.57, 1.07 ± 0.32 in contrast to the placebo group: 0.57
± 0.22, 2.13 ± 0.63, 1.56 ± 0.40. No other interactions
were significant, indicating that the 3 groups performed differently across
time periods. Consistent with the previous findings for the separate analyses
of each time period alone (Table
2), the T-only group (P < .05) correctly reversed more
digits (7.92 ± 0.46) than the T+F group (6.50 ± 0.48) and
placebo group (6.56 ± 0.48). In addition, performance in judging the
angular orientation of lines was overall significantly better (P <
.01) for the T-only group (12.92 ± 0.45) and T+F group (13.21 ±
0.43) compared to the placebo group (11.63 ± 0.47). Finally, the effect
of time was significant (P < .05) for 1 index of verbal memory
performance. Delayed recall of words at baseline was higher (4.57 ±
0.56) compared with 4 months (3.98 ± 0.48) and 36 months (3.75 ±
0.51).
Analyses were also performed combining the T-only and T+F groups and comparing them with the placebo group. Separate between-group analyses of variance at each time period revealed only 1 significant difference (P < .05) at 4 months between the T-treated group compared with the placebo group, with the placebo group recalling fewer total words (38.55 + 1.51) than the T group (42.16 + 0.99). The repeated measures analyses for those participants who completed all 3 assessments again indicated a significant interaction (P < .01) of Group and Time for the number of intrusions, with the T-treated group making fewer errors compared with the placebo group. The performance of the combined T-treated groups on the line-orientation task was better than in the placebo group (P < .01). Finally, a practice effect was found for digits forward (P < .01), with better performance from baseline to 4 months to 36 months.
|
Discussion |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
-reductase inhibitor, showed improved performance in only 1 component
of a test of verbal memory.
Interest in the effects of T on cognition in humans extends from animal
studies of its effect on the brain on both the development and maintenance of
cognitive function (Rosario et al,
2004; Yaffe,
2004). In a recent study in rats, the administration of T and its
nonaromatized metabolites, DHT and 3-androstanediol, all improved
cognitive ability and decreased anxiety
(Edinger and Frye, 2004),
suggesting that T acts in the rodent brain to affect cognitive performance
through aromatization to estrogen or conversion to 5-reduced
nonaromatizable metabolites.
In humans, studies of the effects of T on cognitive function tests in older men with normal, low-normal, or low baseline T levels, have provided mixed results. Similar to our study, Sih et al (1997) enrolled older men with low serum T at baseline and used injectable T for hormone replacement. Although cognitive function was not the primary outcome of the study, tests of memory, recall, and verbal fluency were given to subjects over a period of 12 months of T therapy. The group receiving T had higher baseline function on the cognitive tests, but throughout the study, no improvement or decline occurred, and the difference between the T and placebo groups remained unchanged from baseline. Other randomized placebo-controlled studies of T therapy and cognition in elderly men have included either men with low and low-normal T or men with normal baseline total T levels. In the study by Janowsky et al (2000), some improvement in working memory was seen after 4 weeks of T supplementation in men with baseline low to low-normal T levels. Another study (Cherrier et al, 2001) found that after 6 weeks of T supplementation in men with normal baseline total T levels, verbal memory improved. Both of these studies used injectable T. Two other studies that used scrotal patches to administer T also tested men with normal baseline total T levels. In one study (Kenny et al, 2002), the group receiving hormone replacement had improved performance on Trailmaking B, 1 of 4 cognitive tests administered, but did not differ at any time from the placebo treatment group. In another study (Janowsky et al, 1994), elderly men given supplemental T were found to have improved spatial cognition. The variability among the results of these randomized placebo-controlled trials hints at the complexity of hormonal interactions within the brain. Improvement in cognitive function test scores with T therapy in these studies was seen in elderly men who did not have frankly low levels of T before treatment.
It also is not clear which sex steroids contribute to various domains of cognitive function in men. A prospective study of mildly hypogonadal men receiving either T gel or DHT gel assessed both verbal and spatial cognitive function (Cherrier et al, 2003a). Men receiving T gel showed improvement in verbal memory compared with those receiving DHT gel. This suggests that E2, or other aromatized products of T metabolism, could have an important influence on human verbal cognition. Those receiving only DHT performed better on tests of spatial memory, suggesting the nonaromatized products of T metabolism could have a greater effect on spatial cognition. Several studies have shown that higher levels of E2 negatively affect performance on tests of spatial function (Barrett-Connor et al, 1999b; Janowsky et al, 2000; Cherrier et al, 2003a). Bioavailable T levels might be more closely correlated with cognitive function than total T. Although total T levels might decrease only slightly with increasing age, bioavailable T might decrease by 50% (Barrett-Connor et al, 1999a; Yaffe et al, 2002). In our study, serum DHT levels were significantly lower in the T+F group, whereas serum E2 levels and bioavailable T levels both were higher in the 2 T therapy groups. Although the T-only group showed improved performance on 1 test of attention and the T+F group on 1 test of verbal memory, the treatment groups did not consistently demonstrate improved performance in any specific cognitive domain.
The 50% DHT reduction obtained with the use of finasteride in this study, however, was less than the 70%–80% reduction expected on the basis of studies of finasteride without T replacement (McConnell et al, 1998) and might have occurred because finasteride incompletely blocks the conversion of T to DHT (Rittmaster, 1997), especially in the presence of high serum T levels produced by the T injection regimen. This is mirrored by the prostate-related results, which demonstrated an attenuation of increase, rather than the expected decrease, in both serum PSA and prostate volume with the addition of finasteride (McConnell et al, 1998).
Although cognitive measures were not the primary outcome of our study, the duration of treatment and follow-up of the participants is the first to provide long-term data of the effects of T replacement on cognitive function in men with no obvious cognitive dysfunction at baseline. The dropout rate over the 36 months of the study was high, but analysis of the dropouts' baseline characteristics revealed only a nonsignificant difference in years of education. The educational status of the study participants was very high, with most participants having a college degree, many with a postgraduate degree. It is possible this affected our ability to find differences in cognitive function among groups. Population-based studies of elderly men suggest the relationship between T and certain cognitive functions are U-shaped, such that there is an optimal level of T for some cognitive functions (Muller et al, 2005). With the use of the injectable mode of administration of T in this study, serum levels of T varied greatly over the dosing interval, unlike those that might be found with replacement via patch or gel. Uniformly, however, all of the cognitive testing was done when the serum levels of supplemental T were at their lowest just before the next injection, and previous randomized, placebo-controlled trials of testosterone replacement therapy did not seem to demonstrate any differences in T effect on cognition, whether T was dosed by injection or by patch or gel. Although the men in this study had baseline serum T levels below the range of normal for young adult men, T therapy achieved the same levels of T that have shown effects on cognition in other studies. All of the cognitive assessments were performed by the same individual and at the same time of day and at the same point in the dosing schedule for T, just before the next injection, lessening the risk of variability in performance.
This study, in which we found minimal effects on cognitive test scores with up to 3 years of T therapy in healthy older men with low serum T levels and no significant baseline cognitive dysfunction, adds to the literature reporting inconsistent and doubtful clinically meaningful effects on cognition of T replacement therapy in men who have no evidence of cognitive impairment. Future research on the cognitive effects of T could address whether men who have cognitive impairment from a disorder such as Alzheimer disease might gain functional ability or slowed progression of disease through T replacement. To date, several small studies of T therapy have been made in men with mild to moderate dementia, and these also have provided mixed results. Two such studies reported some improvement in cognitive testing with T therapy (Tan and Pu, 2003; Cherrier et al, 2005), and 2 reported no effect on cognitive function (Kenny et al, 2004; Lu et al, 2006).
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones
and cognitive function in older men. J Clin Endocrinol
Metab. 1999a;84: 3681
-3685.
Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with age: the Rancho-Bernardo Study. J Am Geriatr Soc. 1999b;47: 159 -164.[Medline]
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
measurement of depression. Arch Gen Psychiatry. 1961; 4: 561
-71.
Benton AL. Revised Visual Retention Test: Clinical and Experimental Applications. 4th ed. New York, NY: Psychological Corporation; 1974..
Benton AL, Hamsher KD, Varney NR, Spreen O. Contributions to Neuropsychological Assessment. New York: Oxford University Press; 1983.
Buschke H. Selective reminding analysis of memory and learning. J Verbal Learn Verbal Behav. 1973; 12: 543 -550.[CrossRef]
Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind
E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S.
Testosterone supplementation improves spatial and verbal memory in healthy
older men. Neurology. 2001; 57: 80
-88.
Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated
with supplementation of testosterone or dihydrotestosterone in mildly
hypogonadal men: a preliminary report. J Androl. 2003a; 24: 568
-576.
Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind
ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with
Alzheimer disease and mild cognitive impairment.
Neurology. 2005; 64: 2063
-2068.
Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003b; 170: 1808 -1811.[CrossRef][Medline]
Edinger KL, Frye CA. Testosterone's analgesic, anxiolytic, and
cognitive-enhancing effects may be due in part to actions of its
5-reduced metabolites in the hippocampus. Behav
Neurosci. 2004;118: 1352
-1364.[CrossRef][Medline]
Fonda SJ, Bertrand R, O'Donnell A, Longcope C, McKinlay JB. Age,
hormones, and cognitive functioning among middle-aged and elderly men:
cross-sectional evidence from the Massachusetts Male Aging Study. J
Gerontol A Biol Sci Med Sci. 2005; 60A: 385
-390.
Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J,
Dzekov C, Sinha-Hikim I, Bhasin S. Dose-dependent effects of testosterone on
sexual function, mood, and visuospatial cognition in older men. J
Clin Endocrinol Metab. 2005; 90: 3838
-3846.
Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000; 12: 407 -414.[CrossRef][Medline]
Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994; 108: 325 -332.[CrossRef][Medline]
Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM.
Effects of transdermal testosterone on cognitive function and health
perception in older men with low bioavailable testosterone levels.
J Gerontol A Biol Sci Med Sci. 2002; 57: M321
-M325.
Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004; 59A: 75 -78.[Medline]
Liverman CT, Blazer DG. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2004 .
Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback
E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition
and mood in male patients with mild Alzheimer disease and healthy elderly men.
Arch Neurol. 2006; 63: 177
-185.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Bieber M,
Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM,
Waldstreicher J. The effect of finasteride on the risk of acute urinary
retention and the need for surgical treatment among men with benign prostatic
hyperplasia. Finasteride Long-term Efficacy and Safety Study Group.
N Engl J Med. 1998; 338: 557
-563.
Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick
SM. Longitudinal assessment of serum free testosterone concentration predicts
memory performance and cognitive status in elderly men. J Clin
Endocrinol Metab. 2002;87: 5001
-5007.
Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman
SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men.
Neurology. 2004; 62: 188
-193.
Muller M, Aleman A, Grobbee DE, de Haan EHF, van der Schouw YT.
Endogenous sex hormone levels and cognitive function in aging men. Is there an
optimal level? Neurology. 2005; 64: 866
-871.
Rittmaster RS. 5-Reductase inhibitors. J
Androl. 1997;18: 582
-587.
Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone
depletion and the development of Alzheimer disease.
JAMA. 2004;292: 1431
-1432.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK,
Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S,
Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and
mild cognitive impairment in postmenopausal women: the Women's Health
Initiative Memory Study: a randomized controlled trial.
JAMA. 2003;289: 2651
-2662.
Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C.
Testosterone replacement in older hypogonadal men: a 12-month randomized
controlled trial. J Clin Endocrinol Metab. 1997; 82: 1661
-1667.
Spielberger CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1983 .
Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003;6: 1 -7.[Medline]
US Army. Army Individual Test Battery. Washington, DC: War Department, Adjutant General's Office; 1944 .
Wechsler D. Wechsler Memory Scale-Revised. New York, NY: Psychological Corporation; 1981.
Yaffe K. Testosterone and the brain: uncharted territory. Lancet Neuro. 2004; 3: 270 .
Yaffe K, Lui L-Y, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002; 50: 707 -712.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  L. A. Young, M. B. Neiss, M. H. Samuels, C. E. Roselli, and J. S. Janowsky Cognition Is Not Modified by Large but Temporary Changes in Sex Hormones in Men J. Clin. Endocrinol. Metab., January 1, 2010; 95(1): 280 - 288. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
